Core Viewpoint - The major shareholders of Ruimai Te (301367.SZ) have announced plans to reduce their holdings, which may impact the stock's performance in the market [1][2]. Shareholder Reduction Plans - Nengjin Company and its concerted action partner, Guangzhou Jinyuan, plan to reduce their holdings by up to 888,325 shares, representing 1% of the total share capital, within three months after the announcement [1]. - Hehan Investment and its concerted action partners, Shengmin Chuangtou and Nanjing Hehao, plan to reduce their holdings by up to 2,666,169 shares, representing 3% of the total share capital, within the same timeframe [2]. Shareholding Structure - Nengjin Company holds 4,480,795 shares (5.00% of total shares) and Guangzhou Jinyuan holds 753.325 shares (0.84% of total shares) [3]. - Hehan Investment holds 11,155,686 shares (12.45% of total shares), while Shengmin Chuangtou holds 5,373,515 shares (6.00% of total shares) and Nanjing Hehao holds 358.589 shares (0.40% of total shares) [3]. Reduction Methods and Quantities - Nengjin Company plans to reduce up to 135,000 shares through centralized bidding, while Guangzhou Jinyuan plans to reduce up to 753.325 shares [5]. - Hehan Investment plans to reduce up to 530.134 shares through centralized bidding, and Shengmin Chuangtou plans to reduce up to 1,777,446 shares through block trading [5]. Market Context - Ruimai Te is currently in a state of share price decline, indicating a potential market challenge for the company [9].

证券代码：301367 证券简称：瑞迈特 公告编号：2025-044 北京瑞迈特医疗科技股份有限公司 关于持股5%以上股东及其一致行动人 减持股份的预披露公告 公司股东能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限 合伙）、珠海合晅投资中心（有限合伙）及其一致行动人上海盛旻创业投资合伙 企业（有限合伙）和南京合灏创业投资企业（有限合伙）保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、合计持有本公司股份 5,234,120 股（占本公司总股本比例 5.84%）的股东 能金有限公司及其一致行动人广州市金垣创业投资合伙企业（有限合伙）计划在 自本减持计划公告之日起 15 个交易日后的 3 个月内以集中竞价方式或大宗交易 方式减持本公司股份累计不超过 888,325 股，占本公司总股本比例 1%（总股本 已剔除公司回购专用账户中的股份数量，下同）。 2、合计持有本公司股份 16,887,790 股（占本公司总股本比例 18.85%）的股 东珠海合晅投资中心（ ...

Group 1 - The core point of the announcement is that two major shareholders plan to reduce their holdings in the company through trading methods within a specified timeframe [1] Group 2 - Shareholder Enerjin Limited and its concerted parties plan to reduce their holdings by up to 888,300 shares, which represents 1% of the total share capital [1] - Shareholder Zhuhai Huanxian Investment Center and its concerted parties plan to reduce their holdings by up to 2,666,200 shares, which represents 3% of the total share capital [1] - The reason for the reduction in holdings is due to the shareholders' own financial arrangements [1]

Group 1 - The stock price of Ruimaite (301367.SZ) closed at 79.36 yuan, with a decline of 2.17%, currently below the issue price [1] - Yihe Jiaye was listed on the Shenzhen Stock Exchange's ChiNext on November 1, 2022, with a public offering of 16 million shares, accounting for 25% of the total share capital after issuance, at an issue price of 119.88 yuan per share [1] - The total amount raised by Yihe Jiaye was 191.808 million yuan, with a net amount of 173.82674 million yuan, exceeding the originally planned fundraising by 100.02698 million yuan [1] - The original fundraising plan was 73.79976 million yuan, intended for projects including the production of 300,000 ventilators and 3.5 million sets of accessories, marketing network and brand building, medical equipment R&D center, and working capital [1] - The underwriting institution for Yihe Jiaye was China International Capital Corporation (CICC), with representatives Chen Tingting and Xie Xianming [1] - The total issuance expenses amounted to 18.30202 million yuan, including underwriting and sponsorship fees of 15.71582 million yuan [1] - On May 22, 2024, Yihe Jiaye announced a dividend plan of 10 yuan (pre-tax) per 10 shares, with a bonus issue of 4 shares, with the ex-dividend date set for May 29, 2024 [1] Group 2 - On May 21, 2025, Yihe Jiaye announced a change of company name and stock abbreviation, changing from "Beijing Yihe Jiaye Medical Technology Co., Ltd." to "Beijing Ruimaite Medical Technology Co., Ltd." while the stock code "301367" remains unchanged [2]

Group 1 - The project led by Tianjin Yihejiaye Medical Technology Co., Ltd. won the first prize of Tianjin Science and Technology Progress Award for the research and clinical application of non-invasive respiratory system key technologies [1] - Respiratory diseases have become the third largest chronic disease in China, following cardiovascular diseases and diabetes, with chronic obstructive pulmonary disease and obstructive sleep apnea being the most typical [1] - The non-invasive ventilator is currently the most effective medical device for treating respiratory diseases, with significant technological barriers existing in China compared to developed countries [1] Group 2 - The project achieved breakthroughs in core technologies, key equipment, system platforms, and international standards, possessing complete independent intellectual property rights [1] - A multi-center randomized controlled study was conducted in collaboration with 30 hospitals, focusing on the impact of high-intensity and low-intensity non-invasive positive pressure ventilation on the need for intubation in patients with acute exacerbations of chronic obstructive pulmonary disease [1] - The research results will be published in the Journal of the American Medical Association in 2024 [1] Group 3 - The project team also made advancements in the respiratory chronic disease management system, creating a respiratory data management cloud platform based on data from over 300,000 active users of non-invasive respiratory therapy [2] - The cloud platform connects patients, their families, and doctors, allowing real-time monitoring of sleep-related respiratory data and enabling remote adjustment of treatment parameters by doctors [2] - In 2023, the global market share of Ruimai Te's home non-invasive ventilator was 12.4%, ranking second, while its domestic market share was 30.6%, ranking first among domestic brands [2] Group 4 - As of January 2025, the cumulative sales of Ruimai Te's home ventilators exceeded 3 million units, and the cumulative sales of ventilation masks surpassed 10 million units [2]

Company Overview - Beijing RMT Medical Technology Co., Ltd. was established in 2001 and successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, focusing on home non-invasive ventilators and ventilation masks [2] - RMT is the first domestic company to have non-invasive ventilator products certified by the FDA, with sales in over 100 countries [2] Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Financial Performance - In Q1 2025, the company's overseas revenue reached 170 million CNY, a year-on-year increase of 35.48%, while domestic revenue was 96 million CNY, with a quarter-on-quarter growth of 48.79% and a year-on-year growth of 43.03% [4] - The gross margin for domestic operations was 51.51%, and for overseas operations, it was 48.47%, with both showing an increase compared to the previous quarter [4] Product Launches and Market Strategy - The newly launched P5 series ventilators are primarily targeted at domestic hospital channels, which have a relatively high gross margin [4] - The introduction of the RMT oxygen bottle marks a strategic shift towards the consumer goods market, enhancing brand influence and market share [5] Brand Development - The company's rebranding to "RMT" signifies a strategic alignment between product and capital markets, aiming to enhance brand value [5] - The name "RMT" reflects the company's commitment to respiratory health and smart technology, creating a unified identity across products and capital markets [5] Market Expansion - The company has made adjustments to domestic channel policies and sales strategies, resulting in improved revenue and gross margins in Q1 2025 [5] - In Europe, the company has completed the construction of its cloud platform and is onboarding agents, laying the groundwork for future growth in the mainstream medical insurance market [5]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market on November 1, 2022 [2][3]. - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2][3]. - Ruimait is a leading domestic company in home non-invasive ventilators and masks, with products sold in over 100 countries and regions, holding multiple certifications including NMPA, FDA, and CE [2][3]. Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents. It also has 202 valid overseas patents [3]. Market Position - Ruimait's home non-invasive ventilators hold a 30.6% market share in China, ranking first, and a 12.4% share globally, ranking second in the industry [4][5]. Brand Strategy - The rebranding to "Ruimait" signifies a strategic alignment between product identity and capital market perception, enhancing brand value and market penetration [4][5]. - The name "Ruimait" combines "respiratory" and "smart," reflecting the company's commitment to respiratory health and innovative technology [5]. Product Development - The launch of the Ruimait oxygen bottle marks the company's entry into the consumer goods market, featuring a unique mechanical valve design that enhances oxygen utilization [6]. - The collaboration with Shenzhen Hanyu Pharmaceutical Co., Ltd. aims to develop new products for health consumer channels, targeting mild sleep disorder populations [6][7]. Market Expansion - The company is enhancing its domestic channel strategies and has seen improvements in revenue and gross margin in the first quarter [7][8]. - In Europe, the company has established a cloud platform and onboarded over 20 agents, laying the groundwork for future growth in the mainstream medical insurance market [8].

Core Viewpoint - The company has shown a recovery in performance with Q1 2025 results exceeding expectations, driven by improved order fulfillment in the U.S. market and ongoing domestic growth initiatives [1][3][10] Financial Performance - For 2024, the company reported revenue of 843 million yuan (down 24.85%), net profit attributable to shareholders of 155 million yuan (down 47.74%), and net profit excluding non-recurring items of 92 million yuan (down 61.79%) [2][3] - In Q1 2025, revenue reached 265 million yuan (up 38.11%), net profit attributable to shareholders was 72 million yuan (up 44.11%), and net profit excluding non-recurring items was 60 million yuan (up 43.18%) [2][4] Market Outlook - The company anticipates continued growth in Q2 2025, particularly in the U.S. market, as the low base effect from the previous year supports performance [1][5] - The company plans to enhance brand promotion and channel development in both domestic and international markets throughout the year [1][5][10] Business Segmentation - Revenue from home respiratory therapy products in 2024 was 527 million yuan (down 38.15%), while consumables revenue was 284 million yuan (up 46.22%) [4] - In Q1 2025, home respiratory therapy revenue was 176 million yuan (up 62.80%), and consumables revenue was 81 million yuan (up 7.46%) [4][9] Brand Development - The company changed its name from "怡和嘉业" to "瑞迈特" on May 21, aiming to enhance brand influence and align its corporate identity with its core product offerings [2][5][6] R&D and Innovation - The company is committed to maintaining high levels of R&D investment to improve product performance and expand market share [1][5][10] - Future innovations in respiratory products are expected to leverage AI and brain-machine interface technologies for enhanced functionality [6] Incentive Plans - The company announced a stock incentive plan for 2025, aiming to grant up to 704,000 restricted shares to 54 key personnel, with performance targets set for revenue growth [7]

Group 1: Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003, followed by the first CPAP sleep machine in 2007 [2] - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - Ruimait is a leading domestic company in non-invasive ventilators and masks, being the first domestic company to receive FDA certification for non-invasive ventilators [2][3] Group 2: Market Position and Performance - As of 2023, Ruimait holds a 30.6% market share in the domestic market for home non-invasive ventilators, ranking first, and a 12.4% share globally, ranking second [4] - The company has established a comprehensive product line, including home non-invasive ventilators, masks, sleep monitors, high-flow humidified oxygen therapy devices, and oxygen concentrators [2][3] Group 3: Research and Development - As of December 31, 2024, the company holds 633 valid patents in China, including 107 invention patents, 390 utility model patents, and 136 design patents [3] - The company also has 202 valid overseas patents, including 39 in the United States and 30 in Europe [3] Group 4: Strategic Initiatives - The recent rebranding to "Ruimait" aims to unify product identity and capital market recognition, enhancing brand value and market penetration [5] - A strategic partnership with Shenzhen Hanyu Pharmaceutical Co., Ltd. focuses on joint development of respiratory machines and health products, targeting mild sleep disorder consumers [6] - The company is exploring collaboration with Qiangnao Technology, a leader in non-invasive brain-machine interfaces, to enhance product functionality [7] Group 5: Financial Performance and Market Strategy - In Q1 2025, the company reported an increase in domestic business revenue and gross margin, indicating a stable market performance [8] - The launch of the Ruimait oxygen bottle signifies a strategic shift towards consumer products, aiming to enhance brand influence and market share [10]

Group 1 - Weiling Co., Ltd. announced that its subsidiary Tianjin Changling Mining Partnership acquired 74.3% of Hunan Linwu Jiayu Mining Co., Ltd. for 220 million yuan, focusing on non-ferrous and black metal mining and smelting [1] - Zhongnong Lihua plans to acquire at least 50% of Taizhou Agricultural Materials Co., Ltd., which will become a subsidiary upon completion of the acquisition [1] - Chaohongji is planning to issue H-shares on the Hong Kong Stock Exchange, with details yet to be finalized [1][2] Group 2 - Hong Sifang's subsidiary plans to invest approximately 1.49 billion yuan in a new production base in Suizhou High-tech Industrial Development Zone [3] - Shangwei New Materials announced that its major shareholder Jin Feng Investment Holdings intends to reduce its stake by up to 3%, equating to 12.1 million shares [4] - Yihe Jiaye has changed its name to Beijing Ruimaite Medical Technology Co., Ltd., effective from May 21 [5][6] Group 3 - Huaxi Energy reported that its controlling shareholder has been detained and is under investigation, with no longer holding any positions in the company [7][8] - Aofei Entertainment plans to invest 10 million yuan in a partnership for equity investment in Shenzhen Xuanyuan Technology Co., Ltd. [9] - Hangzhou Electric plans to reduce its shares by up to 1.93%, equating to 13.36 million shares [10] Group 4 - Jiuhua Tourism intends to raise up to 500 million yuan through a private placement for various projects, including hotel renovations and transportation upgrades [11] - Dingxin Communications elected Liu Min as the new chairman following the resignation of Wang Jianhua [12] - Jiewate plans to acquire 40.89% of Nanjing Tianyi Hexin Electronics for 319 million yuan [13] Group 5 - Darui Electronics intends to acquire 80% of Dongguan Weisi Technology Co., Ltd. through cash purchase and capital increase [14] - Tianzhihang's shareholders plan to reduce their stakes by up to 3%, with each shareholder intending to sell 679,000 shares [15][16] - ST Shilong will lift its risk warning and change its stock name to Shilong Industrial, with trading limits adjusted from 5% to 10% [17] Group 6 - Ningde Times announced the listing of its H-shares on the Hong Kong Stock Exchange, raising approximately 35.33 billion HKD [19][20] - Mingyang Electric's shareholders plan to reduce their stakes by up to 3.01%, totaling 941,000 shares [21] - Bohai Leasing intends to transfer 100% of Global Sea Containers Ltd. for 1.75 billion USD, focusing on optimizing its debt structure [21]